Phagos, a French biotech firm, has secured €25 million in Series A funding to deploy its AI-driven p...
The AMW Read
This is an incremental update for a new player in the Vertical AI — Healthcare/Bio segment; the €25M funding round does not meet the $500M threshold for cross.§D.
NoveltySignificance
Healthcare & Bio · Player Map
Phagos, a French biotech firm, has secured €25 million in Series A funding to deploy its AI-driven phage therapy against antibiotic-resistant bacteria. The company's patented AI analyzes phage and bacterial genomes to create highly specific, personalized treatments in as little as two months. This funding validates the urgent need for scalable, AI-enhanced alternatives to traditional antibiotics, first targeting livestock before human applications. The ability to rapidly optimize complex biological treatments marks a major advance in the global fight against antimicrobial resistance.